Stay updated on Anti-CD38 Antibody Trial in CD38+ Malignancies
Sign up to get notified when there's something new on the Anti-CD38 Antibody Trial in CD38+ Malignancies page.

Latest updates to the Anti-CD38 Antibody Trial in CD38+ Malignancies page
- Check2 days agoChange DetectedTel Litwinsky, Israel, 52621 was removed and Qiryat Krinitzi, Israel, 52621 was added to the study's locations. These changes modify the list of participating sites in Israel and may affect where patients can enroll.SummaryDifference0.1%

- Check9 days agoNo Change Detected
- Check16 days agoNo Change Detected
- Check23 days agoChange DetectedRevision label updated from v3.6.4 to v3.6.5, indicating a minor update to the page or its underlying components. This reflects a version increment rather than a substantive change to content.SummaryDifference0.0%

- Check38 days agoChange DetectedRevision label updated from v3.6.3 to v3.6.4 on the page; this represents a small internal update to the page rendering or documentation rather than a change to study information.SummaryDifference0.0%

- Check59 days agoChange DetectedThe page's revision tag was updated from v3.6.2 to v3.6.3, indicating a deployment/patch update. This change is a backend/metadata update and does not modify the study details or the information presented to users.SummaryDifference0.0%

- Check67 days agoChange DetectedThe page now displays Revision: v3.6.2 instead of Revision: v3.6.0, indicating a minor update to the page. This change does not alter the study details shown.SummaryDifference0.0%

- Check81 days agoChange DetectedRecruitment is closed for this study, and new user guidance sections (How to Read a Study Record, Common Questions, How to Join a Study) are added, while the Intervention/Treatment header formatting and the revision label were updated to v3.6.0.SummaryDifference0.2%

Stay in the know with updates to Anti-CD38 Antibody Trial in CD38+ Malignancies
Enter your email address, and we'll notify you when there's something new on the Anti-CD38 Antibody Trial in CD38+ Malignancies page.